Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma

Abstract

Purpose NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas (VS) often causing hearing and neurologic deficits, with currently no FDA-approved drug treatment. Pre-clinical studies highlighted the potential of mTORC1 inhibition in delaying schwannoma progression. We conducted a prospective open-label, phase II study of everolimus for progressive VS in NF2 patients and investigated imaging as a potential biomarker predicting effects on growth trajectory. Methods The trial enrolled 12 NF2 patients with progressive VS. Participants received oral everolimus daily for 52 weeks. Brain imaging was obtained quarterly. As primary endpoint, radiographic response (RR) was defined as ≥ 20% decrease in target VS volume. Secondary endpoints included other tumors RR, hearing outcomes, drug safety and quality of life (QOL). Results Eight participants completed the trial and four discontinued the drug early due to significant volumetric VS progression. After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%. There was no VS RR and 3 of 8 (37.5%) participants had stable disease. Decreased or unchanged VS volume after 3 months of treatment was predictive of stabilization at 12 months. Seven of eight participants had stable hearing during treatment except one with a decline in word recognition score. Ten of twelve participants reported only minimal changes to their QOL scores. Conclusions Volumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011).

mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

“…For instance, the treatment of certain types of cancer and other diseases characterized by abnormal and uncontrolled cell growth has benefited greatly from such inhibitors. Another mTOR inhibitor, everolimus, has been used in the treatment of kidney cancers, as well as breast and brain cancers [ 16 , 17 , 18 ]. Apart from cancer, mTOR inhibitors have also shown promising results in the treatment of genetic disorders such as tuberous sclerosis complex (TSC) and potential benefits in the treatment of neurodegenerative diseases such as Alzheimer’s disease [ 19 ].…”